메뉴 건너뛰기




Volumn 168, Issue 2, 2018, Pages 121-130

Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

EID: 85044412365     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-2073     Document Type: Review
Times cited : (372)

References (78)
  • 1
    • 84928774156 scopus 로고    scopus 로고
    • The future of immune checkpoint therapy
    • [PMID: 25838373]
    • Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61. [PMID: 25838373] doi:10.1126/science.aaa8172
    • (2015) Science , vol.348 , pp. 56-61
    • Sharma, P.1    Allison, J.P.2
  • 2
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • [PMID: 20525992]
    • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. [PMID: 20525992] doi:10.1056/NEJMoa1003466
    • (2010) N Engl J Med. , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3    Weber, R.W.4    Sosman, J.A.5    Haanen, J.B.6
  • 3
    • 84992340907 scopus 로고    scopus 로고
    • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial
    • [PMID: 27592805]
    • Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-85. [PMID: 27592805] doi: 10.1016/S1470-2045(16)30364-3
    • (2016) Lancet Oncol. , vol.17 , pp. 1374-1385
    • Kaufman, H.L.1    Russell, J.2    Hamid, O.3    Bhatia, S.4    Terheyden, P.5    D'Angelo, S.P.6
  • 4
    • 84989918072 scopus 로고    scopus 로고
    • Safety and efficacy of durvalumab (MEDI4736), an antiprogrammed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer
    • [PMID: 27269937]
    • Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an antiprogrammed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016; 34:3119-25. [PMID: 27269937] doi:10.1200/JCO.2016.67.9761
    • (2016) J Clin Oncol. , vol.34 , pp. 3119-3125
    • Massard, C.1    Gordon, M.S.2    Sharma, S.3    Rafii, S.4    Wainberg, Z.A.5    Luke, J.6
  • 5
    • 84907543029 scopus 로고    scopus 로고
    • Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)
    • Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32. doi: 10.1200/jco.2014.32.18-suppl.lba9000
    • (2014) J Clin Oncol. , pp. 32
    • Ribas, A.1    Hodi, F.S.2    Kefford, R.3    Hamid, O.4    Daud, A.5    Wolchok, J.D.6
  • 6
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • [PMID: 25399552]
    • Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30. [PMID: 25399552] doi:10.1056/NEJMoa1412082
    • (2015) N Engl J Med. , vol.372 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3    Dutriaux, C.4    Maio, M.5    Mortier, L.6
  • 7
    • 84908354848 scopus 로고    scopus 로고
    • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
    • [PMID: 25034862]
    • Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17. [PMID: 25034862] doi:10.1016/S0140-6736(14)60958-2
    • (2014) Lancet , vol.384 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3    Hodi, F.S.4    Hamid, O.5    Kefford, R.6
  • 8
    • 84959577118 scopus 로고    scopus 로고
    • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A singlearm, multicentre, phase 2 trial
    • [PMID: 26952546]
    • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet. 2016;387:1909-20. [PMID: 26952546] doi:10.1016/S0140-6736(16)00561-4
    • (2016) Lancet , vol.387 , pp. 1909-1920
    • Rosenberg, J.E.1    Hoffman-Censits, J.2    Powles, T.3    Van Der-Heijden, M.S.4    Balar, A.V.5    Necchi, A.6
  • 9
    • 85013634537 scopus 로고    scopus 로고
    • Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports
    • [PMID: 27472273]
    • Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11: e0160221. [PMID: 27472273] doi:10.1371/journal.pone.0160221
    • (2016) PLoS One , vol.11 , pp. e0160221
    • Abdel-Wahab, N.1    Shah, M.2    Suarez-Almazor, M.E.3
  • 10
    • 84940746759 scopus 로고    scopus 로고
    • Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis
    • [PMID: 26337719]
    • Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015; 13:211. [PMID: 26337719] doi:10.1186/s12916-015-0455-8
    • (2015) BMC Med. , vol.13 , pp. 211
    • Bertrand, A.1    Kostine, M.2    Barnetche, T.3    Truchetet, M.E.4    Schaeverbeke, T.5
  • 11
    • 84965032301 scopus 로고    scopus 로고
    • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    • [PMID: 27141885]
    • Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473-86. [PMID: 27141885] doi:10.1038/nrclinonc.2016.58
    • (2016) Nat Rev Clin Oncol. , vol.13 , pp. 473-486
    • Boutros, C.1    Tarhini, A.2    Routier, E.3    Lambotte, O.4    Ladurie, F.L.5    Carbonnel, F.6
  • 12
    • 84962286789 scopus 로고    scopus 로고
    • Survivorship in immune therapy: Assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center
    • [PMID: 25649350]
    • Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015;3:464-9. [PMID: 25649350] doi:10.1158/2326-6066.CIR-14-0217
    • (2015) Cancer Immunol Res. , vol.3 , pp. 464-469
    • Johnson, D.B.1    Friedman, D.L.2    Berry, E.3    Decker, I.4    Ye, F.5    Zhao, S.6
  • 13
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • [PMID: 26027431]
    • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34. [PMID: 26027431] doi:10.1056/NEJMoa1504030
    • (2015) N Engl J Med. , vol.373 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3    Grob, J.J.4    Cowey, C.L.5    Lao, C.D.6
  • 14
    • 84856862354 scopus 로고    scopus 로고
    • PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer
    • [PMID: 22306905]
    • Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35:169-78. [PMID: 22306905] doi:10.1097/CJI.0b013e318247a4e7
    • (2012) J Immunother. , vol.35 , pp. 169-178
    • Dulos, J.1    Carven, G.J.2    Van Boxtel, S.J.3    Evers, S.4    Driessen-Engels, L.J.5    Hobo, W.6
  • 15
    • 67649268353 scopus 로고    scopus 로고
    • CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
    • [PMID: 19457253]
    • von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35. [PMID: 19457253] doi:10.1186/1479-5876-7-35
    • (2009) J Transl Med. , vol.7 , pp. 35
    • Von Euw, E.1    Chodon, T.2    Attar, N.3    Jalil, J.4    Koya, R.C.5    Comin-Anduix, B.6
  • 16
    • 84984663113 scopus 로고    scopus 로고
    • Checkpoint immunotherapy: Good for cancer therapy, bad for rheumatic diseases [Editorial]
    • [PMID: 27566797]
    • Calabrese L, Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases [Editorial]. Ann Rheum Dis. 2017;76:1-3. [PMID: 27566797] doi:10.1136/annrheumdis-2016-209782
    • (2017) Ann Rheum Dis. , vol.76 , pp. 1-3
    • Calabrese, L.1    Velcheti, V.2
  • 18
    • 34248383514 scopus 로고    scopus 로고
    • Guidelines for submitting adverse event reports for publication
    • International Society for Pharmacoepidemiology [PMID: 17472416]
    • Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, et al; International Society for Pharmacoepidemiology. Guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30:367-73. [PMID: 17472416]
    • (2007) Drug Saf. , vol.30 , pp. 367-373
    • Kelly, W.N.1    Arellano, F.M.2    Barnes, J.3    Bergman, U.4    Edwards, R.I.5    Fernandez, A.M.6
  • 19
    • 84888248267 scopus 로고    scopus 로고
    • Melanoma-associated retinopathy treated with ipilimumab therapy
    • [PMID: 24051549]
    • Audemard A, de Raucourt S, Miocque S, Comoz F, Giraud JM, Dreno B, et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology. 2013;227:146-9. [PMID: 24051549] doi:10.1159/000353408
    • (2013) Dermatology , vol.227 , pp. 146-149
    • Audemard, A.1    De Raucourt, S.2    Miocque, S.3    Comoz, F.4    Giraud, J.M.5    Dreno, B.6
  • 21
    • 84958985225 scopus 로고    scopus 로고
    • Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer
    • Bagley SJ, Kosteva JA, Evans TL, Langer CJ. Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treat Commun. 2016;6:20-3.
    • (2016) Cancer Treat Commun. , vol.6 , pp. 20-23
    • Bagley, S.J.1    Kosteva, J.A.2    Evans, T.L.3    Langer, C.J.4
  • 22
    • 85015907153 scopus 로고    scopus 로고
    • Hyperthyroidism followed by worsening primary hypothyroidism in a patient treated with ipilimumab and pembrolizumab
    • Batacchi Z, Alarcon-Casas Wright L. Hyperthyroidism followed by worsening primary hypothyroidism in a patient treated with ipilimumab and pembrolizumab. Thyroid. 2015;25:A215.
    • (2015) Thyroid. , vol.25 , pp. A215
    • Batacchi, Z.1    Alarcon-Casas Wright, L.2
  • 23
    • 85020929887 scopus 로고    scopus 로고
    • Nivolumab-induced granulomatous inflammation of the pleura [Letter]
    • [PMID: 28629542]
    • Benn BS, Lombard CM, Krishna G. Nivolumab-induced granulomatous inflammation of the pleura [Letter]. J Thorac Oncol. 2017;12: e100-1. [PMID: 28629542] doi:10.1016/j.jtho.2017.03.006
    • (2017) J Thorac Oncol. , vol.12 , pp. e100-e101
    • Benn, B.S.1    Lombard, C.M.2    Krishna, G.3
  • 24
    • 84997610273 scopus 로고    scopus 로고
    • Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
    • [PMID: 25992290]
    • Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3:19. [PMID: 25992290] doi:10.1186/s40425-015-0064-2
    • (2015) J Immunother Cancer , vol.3 , pp. 19
    • Bostwick, A.D.1    Salama, A.K.2    Hanks, B.A.3
  • 25
    • 84971324112 scopus 로고    scopus 로고
    • Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC)
    • [PMID: 27163740]
    • Chia PL, John T. Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother. 2016;39:202-4. [PMID: 27163740] doi: 10.1097/CJI.0000000000000121
    • (2016) J Immunother. , vol.39 , pp. 202-204
    • Chia, P.L.1    John, T.2
  • 26
    • 85044402169 scopus 로고    scopus 로고
    • Granulomatosis with polyangiitis associated with immune checkpoint blockade: Case report and literature review
    • Cusnir I, Solez K, Yacyshyn E. Granulomatosis with polyangiitis associated with immune checkpoint blockade: case report and literature review. J Rheumatol. 2017;44(Suppl 6):950.
    • (2017) J Rheumatol. , vol.44 , pp. 950
    • Cusnir, I.1    Solez, K.2    Yacyshyn, E.3
  • 27
    • 85019873747 scopus 로고    scopus 로고
    • Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade [Letter]
    • [PMID: 28514612]
    • Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade [Letter]. N Engl J Med. 2017;376:1989-91. [PMID: 28514612] doi:10.1056/NEJMc1703047
    • (2017) N Engl J Med. , vol.376 , pp. 1989-1991
    • Esfahani, K.1    Miller, W.H.2
  • 28
    • 84981250350 scopus 로고    scopus 로고
    • CTLA4 as immunological checkpoint in the development of multiple sclerosis
    • [PMID: 27351142]
    • Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol. 2016;80:294-300. [PMID: 27351142] doi:10.1002/ana.24715
    • (2016) Ann Neurol. , vol.80 , pp. 294-300
    • Gerdes, L.A.1    Held, K.2    Beltrán, E.3    Berking, C.4    Prinz, J.C.5    Junker, A.6
  • 29
    • 84952785505 scopus 로고    scopus 로고
    • Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma [Letter]
    • [PMID: 25257614]
    • Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma [Letter]. Mult Scler. 2015;21:670. [PMID: 25257614] doi:10.1177/1352458514549403
    • (2015) Mult Scler. , vol.21 , pp. 670
    • Gettings, E.J.1    Hackett, C.T.2    Scott, T.F.3
  • 30
    • 84918517634 scopus 로고    scopus 로고
    • Ipilimumab in a patient with known Crohn's disease: To give or not to give? [Letter]
    • [PMID: 25154682]
    • Gielisse EA, de Boer NK. Ipilimumab in a patient with known Crohn's disease: to give or not to give? [Letter]. J Crohns Colitis. 2014;8:1742. [PMID: 25154682] doi:10.1016/j.crohns.2014.08.002
    • (2014) J Crohns Colitis , vol.8 , pp. 1742
    • Gielisse, E.A.1    De Boer, N.K.2
  • 31
    • 85058904959 scopus 로고    scopus 로고
    • Myasthenic syndrome with pembrolizumab use
    • Hegde U, Chauhan A, Desai N. Myasthenic syndrome with pembrolizumab use. Neurology. 2017;88(Suppl P6.175):1526-632X.
    • (2017) Neurology. , vol.88 , pp. 1526X-1632X
    • Hegde, U.1    Chauhan, A.2    Desai, N.3
  • 32
    • 84962198249 scopus 로고    scopus 로고
    • Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy [Letter]
    • [PMID: 25805871]
    • Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy [Letter]. Diabetes Care. 2015;38:e55-7. [PMID: 25805871] doi:10.2337/dc14-2349
    • (2015) Diabetes Care , vol.38 , pp. e55-e57
    • Hughes, J.1    Vudattu, N.2    Sznol, M.3    Gettinger, S.4    Kluger, H.5    Lupsa, B.6
  • 35
    • 85015837474 scopus 로고    scopus 로고
    • Ipilimumab-induced colitis in a patient with ulcerative colitis and lung cancer
    • Kamil F, Cohen M, Kumta N, Wan D. Ipilimumab-induced colitis in a patient with ulcerative colitis and lung cancer. Am J Gastroenterol. 2013;108:S404.
    • (2013) Am J Gastroenterol , vol.108 , pp. S404
    • Kamil, F.1    Cohen, M.2    Kumta, N.3    Wan, D.4
  • 36
    • 84945294851 scopus 로고    scopus 로고
    • Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma [Letter]
    • [PMID: 26388113]
    • Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma [Letter]. J Eur Acad Dermatol Venereol. 2016;30:e89-91. [PMID: 26388113] doi:10.1111/jdv.13336
    • (2016) J Eur Acad Dermatol Venereol. , vol.30 , pp. e89-e91
    • Kato, Y.1    Otsuka, A.2    Miyachi, Y.3    Kabashima, K.4
  • 37
    • 85015411251 scopus 로고    scopus 로고
    • Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: A case report
    • [PMID: 28315636]
    • Kwatra V, Karanth NV, Priyadarshana K, Charakidis M. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. J Med Case Rep. 2017;11:73. [PMID: 28315636] doi:10.1186/s13256-017-1229-z
    • (2017) J Med Case Rep. , vol.11 , pp. 73
    • Kwatra, V.1    Karanth, N.V.2    Priyadarshana, K.3    Charakidis, M.4
  • 38
    • 84977136814 scopus 로고    scopus 로고
    • Ipilimumab in patients with melanoma and autoimmune disease
    • [PMID: 25349698]
    • Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2:35. [PMID: 25349698] doi:10.1186/s40425-014-0035-z
    • (2014) J Immunother Cancer , vol.2 , pp. 35
    • Kyi, C.1    Carvajal, R.D.2    Wolchok, J.D.3    Postow, M.A.4
  • 39
    • 84975078639 scopus 로고    scopus 로고
    • Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
    • [PMID: 27065302]
    • Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54:157-61. [PMID: 27065302] doi:10.1002/mus.25141
    • (2016) Muscle Nerve. , vol.54 , pp. 157-161
    • Lau, K.H.1    Kumar, A.2    Yang, I.H.3    Nowak, R.J.4
  • 40
    • 85015914196 scopus 로고    scopus 로고
    • A case of myasthenia gravis exacerbation in a patient with melanoma treated with pembrolizumab
    • Lau KHV, Kumar A, Yang I, Nowak R. A case of myasthenia gravis exacerbation in a patient with melanoma treated with pembrolizumab. Neurology. 2016;86(Suppl P3.138).
    • (2016) Neurology , vol.86
    • Lau, K.H.V.1    Kumar, A.2    Yang, I.3    Nowak, R.4
  • 41
    • 84994158163 scopus 로고    scopus 로고
    • Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis
    • [PMID: 27019533]
    • Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78:119-22. [PMID: 27019533]
    • (2016) Nagoya J Med Sci. , vol.78 , pp. 119-122
    • Maeda, O.1    Yokota, K.2    Atsuta, N.3    Katsuno, M.4    Akiyama, M.5    Ando, Y.6
  • 42
    • 84954554294 scopus 로고    scopus 로고
    • Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma
    • [PMID: 26270860]
    • Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol. 2016;96:259-60. [PMID: 26270860] doi:10.2340/00015555-2212
    • (2016) Acta Derm Venereol. , vol.96 , pp. 259-260
    • Matsumura, N.1    Ohtsuka, M.2    Kikuchi, N.3    Yamamoto, T.4
  • 43
    • 84961942697 scopus 로고    scopus 로고
    • Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease
    • [PMID: 27023060]
    • Maul LV, Weichenthal M, Kähler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016;39:188-90. [PMID: 27023060] doi:10.1097/CJI.0000000000000118
    • (2016) J Immunother. , vol.39 , pp. 188-190
    • Maul, L.V.1    Weichenthal, M.2    Kähler, K.C.3    Hauschild, A.4
  • 44
    • 84956840392 scopus 로고    scopus 로고
    • Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
    • [PMID: 26198822]
    • Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, et al. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43:210-4. [PMID: 26198822] doi:10.1111/1346-8138.13028
    • (2016) J Dermatol. , vol.43 , pp. 210-214
    • Narita, T.1    Oiso, N.2    Taketomo, Y.3    Okahashi, K.4    Yamauchi, K.5    Sato, M.6
  • 46
    • 84916205029 scopus 로고    scopus 로고
    • Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
    • [PMID: 25227926]
    • Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, et al. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63: 1341-6. [PMID: 25227926] doi:10.1007/s00262-014-1607-y
    • (2014) Cancer Immunol Immunother , vol.63 , pp. 1341-1346
    • Pedersen, M.1    Andersen, R.2    Nørgaard, P.3    Jacobsen, S.4    Thielsen, P.5    Thor Straten, P.6
  • 47
    • 85050580151 scopus 로고    scopus 로고
    • Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: A report of 2 patient cases
    • 2324709616674316 [PMID: 27826593]
    • Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316. [PMID: 27826593]
    • (2016) J Investig Med High Impact Case Rep. , vol.4
    • Phadke, S.D.1    Ghabour, R.2    Swick, B.L.3    Swenson, A.4    Milhem, M.5    Zakharia, Y.6
  • 48
    • 85016348948 scopus 로고    scopus 로고
    • Induction of muscular sarcoidosis in a metastastic melanoma patient treated with ipilimumab
    • Plachouri KM, Mohr M, Sunderkotter C, Weishaupt C. Induction of muscular sarcoidosis in a metastastic melanoma patient treated with ipilimumab. J Dtsch Dermatol Ges. 2012;10:861.
    • (2012) J Dtsch Dermatol Ges. , vol.10 , pp. 861
    • Plachouri, K.M.1    Mohr, M.2    Sunderkotter, C.3    Weishaupt, C.4
  • 49
    • 85044433170 scopus 로고    scopus 로고
    • The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis
    • [PMID: 28817445]
    • Puri A, Homsi J. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. Melanoma Res. 2017;27:519-23. [PMID: 28817445] doi:10.1097/CMR.0000000000000387
    • (2017) Melanoma Res. , vol.27 , pp. 519-523
    • Puri, A.1    Homsi, J.2
  • 50
    • 84997235698 scopus 로고    scopus 로고
    • Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab
    • [PMID: 27540851]
    • Roberts P, Fishman GA, Joshi K, Jampol LM. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134:1184-8. [PMID: 27540851] doi:10.1001/jamaophthalmol.2016.2944
    • (2016) JAMA Ophthalmol , vol.134 , pp. 1184-1188
    • Roberts, P.1    Fishman, G.A.2    Joshi, K.3    Jampol, L.M.4
  • 51
    • 85044411787 scopus 로고    scopus 로고
    • Treatment of Merkel cell carcinoma with pembrolizumab in a patient with psoriasis and psoriatic arthritis
    • Roche L, Murphy M, Power D. Treatment of Merkel cell carcinoma with pembrolizumab in a patient with psoriasis and psoriatic arthritis. Br J Dermatol. 2017;177(Suppl 1):140-54.
    • (2017) Br J Dermatol. , vol.177 , pp. 140-154
    • Roche, L.1    Murphy, M.2    Power, D.3
  • 53
    • 84974846127 scopus 로고    scopus 로고
    • Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
    • [PMID: 26951628]
    • Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135-7. [PMID: 26951628] doi:10.1093/annonc/mdw130
    • (2016) Ann Oncol. , vol.27 , pp. 1135-1137
    • Spain, L.1    Higgins, R.2    Gopalakrishnan, K.3    Turajlic, S.4    Gore, M.5    Larkin, J.6
  • 54
    • 84984920567 scopus 로고    scopus 로고
    • Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: A case report
    • [PMID: 27595932]
    • Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016;9:81. [PMID: 27595932] doi:10.1186/s13045-016-0309-7
    • (2016) J Hematol Oncol. , vol.9 , pp. 81
    • Uemura, M.1    Trinh, V.A.2    Haymaker, C.3    Jackson, N.4    Kim, D.W.5    Allison, J.P.6
  • 55
    • 85016355628 scopus 로고    scopus 로고
    • Muscular sarcoidosis in a metastatic melanoma patient treated with ipilimumab
    • Weishaupt C, Mohr M, Sunderkotter C. Muscular sarcoidosis in a metastatic melanoma patient treated with ipilimumab. J Dtsch Dermatol Ges. 2012;10:683.
    • (2012) J Dtsch Dermatol Ges. , vol.10 , pp. 683
    • Weishaupt, C.1    Mohr, M.2    Sunderkotter, C.3
  • 56
    • 84982171125 scopus 로고    scopus 로고
    • Myasthenia gravis exacerbation associated with pembrolizumab
    • [PMID: 26802533]
    • Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54:506-7. [PMID: 26802533] doi:10.1002/mus.25055
    • (2016) Muscle Nerve. , vol.54 , pp. 506-507
    • Zhu, J.1    Li, Y.2
  • 57
    • 85016342140 scopus 로고    scopus 로고
    • Anti-CTLA-4 antibody therapy causing autoimmune hypophysitis in a patient with a longstanding history of Hashimotos's thyroiditis
    • Zmeili O, Samantray J. Anti-CTLA-4 antibody therapy causing autoimmune hypophysitis in a patient with a longstanding history of Hashimotos's thyroiditis. Endocr Rev. 2013;1.
    • (2013) Endocr Rev. , pp. 1
    • Zmeili, O.1    Samantray, J.2
  • 58
    • 85012893091 scopus 로고    scopus 로고
    • Vedolizumab treatment for immune checkpoint inhibitorinduced enterocolitis
    • [PMID: 28204866]
    • Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitorinduced enterocolitis. Cancer Immunol Immunother. 2017;66:581-92. [PMID: 28204866] doi:10.1007/s00262-017-1962-6
    • (2017) Cancer Immunol Immunother. , vol.66 , pp. 581-592
    • Bergqvist, V.1    Hertervig, E.2    Gedeon, P.3    Kopljar, M.4    Griph, H.5    Kinhult, S.6
  • 59
    • 84998706924 scopus 로고    scopus 로고
    • Anti-PD1-induced psoriasis: A study of 21 patients [Letter]
    • Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie [PMID: 27739129]
    • Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al; Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie. Anti-PD1-induced psoriasis: a study of 21 patients [Letter]. J Eur Acad Dermatol Venereol. 2017;31:e254-7. [PMID: 27739129] doi:10.1111/jdv.14011
    • (2017) J Eur Acad Dermatol Venereol. , vol.31 , pp. e254-e257
    • Bonigen, J.1    Raynaud-Donzel, C.2    Hureaux, J.3    Kramkimel, N.4    Blom, A.5    Jeudy, G.6
  • 60
    • 85015958229 scopus 로고    scopus 로고
    • Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity
    • [PMID: 28405474]
    • Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3: e000412. [PMID: 28405474] doi:10.1136/rmdopen-2016-000412
    • (2017) RMD Open , vol.3 , pp. e000412
    • Calabrese, C.1    Kirchner, E.2    Kontzias, K.3    Velcheti, V.4    Calabrese, L.H.5
  • 61
    • 84974824082 scopus 로고    scopus 로고
    • The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma [Letter]
    • [PMID: 26861600]
    • Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma [Letter]. Ann Oncol. 2016;27:1174-7. [PMID: 26861600] doi:10.1093/annonc/mdw056
    • (2016) Ann Oncol. , vol.27 , pp. 1174-1177
    • Lee, B.1    Wong, A.2    Kee, D.3    Neeson, P.4    Shackleton, M.5    McArthur, G.6
  • 62
    • 85029681029 scopus 로고    scopus 로고
    • PD-1 inhibitorassociated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-report of 4 cases
    • [PMID: 28753231]
    • Chou S, Zhao C, Hwang SJE, Fernandez-Penas P. PD-1 inhibitorassociated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-report of 4 cases. J Cutan Pathol. 2017;44: 851-6. [PMID: 28753231] doi:10.1111/cup.13013
    • (2017) J Cutan Pathol. , vol.44 , pp. 851-856
    • Chou, S.1    Zhao, C.2    Hwang, S.J.E.3    Fernandez-Penas, P.4
  • 63
    • 85013175346 scopus 로고    scopus 로고
    • Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
    • German Dermatooncology Group (DeCOG) [PMID: 28214654]
    • Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al; German Dermatooncology Group (DeCOG). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24-32. [PMID: 28214654] doi: 10.1016/j.ejca.2016.12.038
    • (2017) Eur J Cancer , vol.75 , pp. 24-32
    • Gutzmer, R.1    Koop, A.2    Meier, F.3    Hassel, J.C.4    Terheyden, P.5    Zimmer, L.6
  • 65
    • 85003054266 scopus 로고    scopus 로고
    • Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
    • [PMID: 26633184]
    • Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234-40. [PMID: 26633184] doi:10.1001/jamaoncol.2015.4368.
    • (2016) JAMA Oncol. , vol.2 , pp. 234-240
    • Johnson, D.B.1    Sullivan, R.J.2    Ott, P.A.3    Carlino, M.S.4    Khushalani, N.I.5    Ye, F.6
  • 66
    • 85021128995 scopus 로고    scopus 로고
    • Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/antiprogrammed cell death-ligand 1 agents: A single-centre pharmacovigilance database analysis
    • [PMID: 28646772]
    • Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/antiprogrammed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34-44. [PMID: 28646772] doi:10.1016/j.ejca.2017.05.032
    • (2017) Eur J Cancer , vol.82 , pp. 34-44
    • Le Burel, S.1    Champiat, S.2    Mateus, C.3    Marabelle, A.4    Michot, J.M.5    Robert, C.6
  • 67
    • 85044424850 scopus 로고    scopus 로고
    • Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy [Letter]
    • [PMID: 28242618]
    • Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy [Letter]. Ann Rheum Dis. 2017. [PMID: 28242618] doi:10.1136/annrheumdis-2016-210820
    • (2017) Ann Rheum Dis.
    • Le Burel, S.1    Champiat, S.2    Routier, E.3    Aspeslagh, S.4    Albiges, L.5    Szwebel, T.A.6
  • 68
    • 84892866206 scopus 로고    scopus 로고
    • Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma
    • [PMID: 24145345]
    • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol. 2013;31:4311-8. [PMID: 24145345] doi:10.1200/JCO.2013.51.4802
    • (2013) J Clin Oncol. , vol.31 , pp. 4311-4318
    • Weber, J.S.1    Kudchadkar, R.R.2    Yu, B.3    Gallenstein, D.4    Horak, C.E.5    Inzunza, H.D.6
  • 69
    • 4444354041 scopus 로고    scopus 로고
    • Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus
    • [PMID: 15138458]
    • Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004;12:620-6. [PMID: 15138458]
    • (2004) Eur J Hum Genet. , vol.12 , pp. 620-626
    • Barreto, M.1    Santos, E.2    Ferreira, R.3    Fesel, C.4    Fontes, M.F.5    Pereira, C.6
  • 70
    • 84939892080 scopus 로고    scopus 로고
    • Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility
    • [PMID: 24942602]
    • Lee YH, Bae SC, Kim JH, Song GG. Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol. 2015;74:230-9. [PMID: 24942602] doi:10.1007/s00393-014-1415-y
    • (2015) Z Rheumatol. , vol.74 , pp. 230-239
    • Lee, Y.H.1    Bae, S.C.2    Kim, J.H.3    Song, G.G.4
  • 71
    • 84896548089 scopus 로고    scopus 로고
    • CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: A meta-analysis
    • [PMID:24530750]
    • Lee YH, Kim JH, Seo YH, Choi SJ, Ji JD, Song GG. CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol.2014;75:414-21.[PMID:24530750]doi: 10.1016/j.humimm.2014.02.020
    • (2014) Hum Immunol. , vol.75 , pp. 414-421
    • Lee, Y.H.1    Kim, J.H.2    Seo, Y.H.3    Choi, S.J.4    Ji, J.D.5    Song, G.G.6
  • 72
    • 62749182367 scopus 로고    scopus 로고
    • Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: A meta-analysis
    • [PMID: 19074163]
    • Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus. 2009;18:9-15. [PMID: 19074163] doi: 10.1177/0961203308093923
    • (2009) Lupus. , vol.18 , pp. 9-15
    • Lee, Y.H.1    Woo, J.H.2    Choi, S.J.3    Ji, J.D.4    Song, G.G.5
  • 73
    • 84910101471 scopus 로고    scopus 로고
    • The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: A meta-analysis
    • [PMID: 25128482]
    • Li G, Shi F, Liu J, Li Y. The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis. Diagn Pathol. 2014;9: 157. [PMID: 25128482] doi:10.1186/s13000-014-0157-0
    • (2014) Diagn Pathol. , vol.9 , pp. 157
    • Li, G.1    Shi, F.2    Liu, J.3    Li, Y.4
  • 74
    • 62149115181 scopus 로고    scopus 로고
    • Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: A meta-analysis
    • [PMID: 19220647]
    • Liu JL, Zhang FY, Liang YH, Xiao FL, Zhang SQ, Cheng YL, et al. Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J Eur Acad Dermatol Venereol. 2009;23:425-32. [PMID: 19220647] doi:10.1111/j.1468-3083.2009.03087.x
    • (2009) J Eur Acad Dermatol Venereol. , vol.23 , pp. 425-432
    • Liu, J.L.1    Zhang, F.Y.2    Liang, Y.H.3    Xiao, F.L.4    Zhang, S.Q.5    Cheng, Y.L.6
  • 75
    • 47249153181 scopus 로고    scopus 로고
    • CTLA-4: A key regulatory point in the control of autoimmune disease
    • [PMID: 18613834]
    • Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143-55. [PMID: 18613834] doi:10.1111/j.1600-065X.2008.00639.x
    • (2008) Immunol Rev. , vol.223 , pp. 143-155
    • Scalapino, K.J.1    Daikh, D.I.2
  • 76
    • 85016830728 scopus 로고    scopus 로고
    • The association between CTLA-4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: A meta-analysis
    • [PMID: 26176417]
    • Wu J, Zhang L, Zhou Y. The association between CTLA-4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: a meta-analysis. Int J Rheum Dis. 2016;19:1237-43. [PMID: 26176417] doi:10.1111/1756-185X.12705
    • (2016) Int J Rheum Dis. , vol.19 , pp. 1237-1243
    • Wu, J.1    Zhang, L.2    Zhou, Y.3
  • 77
    • 85030215805 scopus 로고    scopus 로고
    • Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature
    • [PMID: 27998041]
    • Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69:1751-63. [PMID: 27998041] doi:10.1002/acr.23177
    • (2017) Arthritis Care Res (Hoboken) , vol.69 , pp. 1751-1763
    • Cappelli, L.C.1    Gutierrez, A.K.2    Bingham, C.O.3    Shah, A.A.4
  • 78
    • 85019333926 scopus 로고    scopus 로고
    • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
    • [PMID: 27687304]
    • Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368-76. [PMID: 27687304] doi: 10.1093/annonc/mdw443
    • (2017) Ann Oncol. , vol.28 , pp. 368-376
    • Menzies, A.M.1    Johnson, D.B.2    Ramanujam, S.3    Atkinson, V.G.4    Wong, A.N.M.5    Park, J.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.